<!DOCTYPE html><html><head><meta charset='utf-8'><title>Clinical Pharmacology Summary – ADA Drug Interference & PandA Correction</title>
<style>
body { font-family: -apple-system, Segoe UI, Roboto, Helvetica, Arial, sans-serif; line-height: 1.45; max-width: 860px; margin: 2rem auto; padding: 0 1rem; }
h1, h2, h3 { line-height: 1.2; }
img { max-width: 100%; height: auto; border: 1px solid #eee; padding: 4px; background: #fafafa; }
code { background: #f6f8fa; padding: 0.2em 0.4em; border-radius: 4px; }
hr { border: 0; height: 1px; background: #eee; margin: 2rem 0; }
</style>
</head><body><h1>Clinical Pharmacology Summary – ADA Drug Interference &amp; PandA Correction</h1>
<p><strong>Product:</strong> Monoclonal X • <strong>Sponsor:</strong> Demo Biotech • <strong>Date:</strong> 2025-10-25</p>
<h2>1. Bioanalytical Methods &amp; Interference</h2>
<p>PandA (PEG + Acid) improves drug tolerance vs standard bridging (≥80% recovery up to ≥100 µg/mL).</p>
<p><img alt="Drug tolerance" src="/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/recovery_overlay_sim_vs_lit.png" /></p>
<p><strong>PASS/ALERT summary</strong></p>
<p><img alt="PASS/ALERT table" src="/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/pass_alert_table.png" /></p>
<h2>2. Population PK &amp; Variability (brief)</h2>
<p>At Week 52, ADA⁺ subjects show reduced troughs.</p>
<p><img alt="Week-52 troughs by detected ADA" src="/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/wk52_by_detected_ADA_assay.png" /></p>
<h2>3. Exposure–Response &amp; Target Attainment</h2>
<p>True exposure–response shows reduced efficacy at low troughs.</p>
<p><img alt="True exposure–response" src="/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/exposure_response_true.png" /></p>
<p>Target attainment table (CSV): <code>/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/TLG_target_attainment.csv</code></p>
<h2>4. Dose Recommendation (draft)</h2>
<p>Use <strong>PandA-based immunogenicity</strong> for PK/E–R decisions at therapeutic drug levels.
If program requires ≥X% target attainment, consider dose adjustment <strong>only if</strong> safety margin allows.</p>
<h2>5. Conclusions</h2>
<ul>
<li>Standard bridging fails tolerance benchmark; PandA passes.</li>
<li>Bioanalytical method selection materially changes PK/E–R interpretation and dose justification.</li>
</ul></body></html>